{"id":943177,"date":"2026-03-10T09:32:34","date_gmt":"2026-03-10T13:32:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/"},"modified":"2026-03-10T09:32:34","modified_gmt":"2026-03-10T13:32:34","slug":"aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/","title":{"rendered":"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March  10, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong> Aptorum Group Limited (NASDAQ: APM) (&#8220;Aptorum Group\u201d or \u201cAptorum\u201d), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (\u201cDiamiR\u201d), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, <i>et. al.<\/i> titled <i>&#8220;Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens\u201d <\/i>in <i>Diagnostics, <\/i>(<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zpDHVGEtZLPJZxMNuj46H716nn1Ttvioe5CQ-Jik8_hm55cQSp8hsXmxCHKaeA51B12c_LJZntM58HieXaPc2WCuu4QoDe1AqfgUI2WuGAQr1EDzmCK11vJWykfqA5_P0pbvu_lPCKWjuP0Bt1LXZtFCtQDHwDRqUbmDvHJE3MQ=\" rel=\"nofollow\" target=\"_blank\">https:\/\/doi.org\/10.3390\/diagnostics16050791<\/a>), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.<\/p>\n<p align=\"justify\">This study, conducted in collaboration with clinical researchers at the Perelman School of Medicine at the University of Pennsylvania, demonstrates the feasibility of detecting glioblastoma (GBM) \u2014 the most aggressive and lethal form of brain cancer \u2014 through a minimally invasive blood plasma test. The research identifies specific microRNA signatures in blood plasma that show significant promise as non-invasive biomarkers for glioblastoma diagnosis and monitoring.<\/p>\n<p align=\"justify\">GBM is among the deadliest of all human cancers, with a median survival of fewer than 15 months following diagnosis. Current diagnostic approaches rely on invasive surgical biopsies or costly imaging procedures. DiamiR\u2019s microRNA platform represents a potential paradigm shift, one that we believe will enable earlier detection and improve patient monitoring through a simple blood draw.<\/p>\n<p align=\"justify\">According to Alidad Mireskandari, Ph.D., Chief Executive Officer of DiamiR, \u201cWe are proud to announce the publication of our latest peer-reviewed data demonstrating the clinical potential of microRNA biomarkers in the detection of glioblastoma. This work builds on a growing body of evidence supporting the role of microRNAs in Brain Health and represents an important validation of our platform. I\u2019m grateful to our team and collaborators at The University of Pennsylvania Perelman School of Medicine for their thoughtful work behind this publication. Glioblastoma remains an incredibly challenging disease, and I hope this work adds constructively to the broader effort to better understand and treat this cancer.\u201d<\/p>\n<p align=\"justify\">Mireskandari added that \u201cImportantly, this work is not a standalone milestone \u2014 it advances our broader pipeline strategy, which is focused on translating microRNA biology into clinically actionable solutions across high-unmet-need indications. We believe this technology has the potential to transform how devastating diseases like GBM are detected and monitored, and this publication marks a meaningful step forward in bringing that vision to patients and clinicians.\u201d<\/p>\n<p align=\"justify\">Stephen Bagley, MD, Section Chief, Neuro-Oncology, Hematology-Oncology, and Associate Professor of Medicine (Hematology-Oncology) at the University of Pennsylvania and the senior author on the paper, said \u201cThese results are exciting and set the stage for larger clinical studies, which we hope will prove the clinical utility of plasma microRNA signatures for diagnosis and monitoring of brain tumors. Our patients desperately need noninvasive tests to help inform their care, and this study is a positive step in that direction.\u201d<\/p>\n<p align=\"justify\">\n        <b>About Aptorum Group<\/b>\n      <\/p>\n<p align=\"justify\">Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XerVKyR5uMrpbDpqJGqVtvC85AdUOO66kmXj7nr-ZPipW5_oWM6t8qBSFrmscW-3NUOeIZFfZkPf2lzd6cBRSN664XemKSHDeP_EHQxCcB8=\" rel=\"nofollow\" target=\"_blank\">www.aptorumgroup.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>About DiamiR<\/b>\n      <\/p>\n<p align=\"justify\">DiamiR Biosciences is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA-certified, CAP-accredited laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR\u2019s proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vdqEOCxD23mRmk_6d3W13pCqVa0JbIEphAyYAxBkhw-NR18Qt8fzJ9yC_BZ00fdbLb7jxMaso58sO2wAfzxpcr6oRPYwST1benJzhvT2JU0=\" rel=\"nofollow\" target=\"_blank\">www.diamirbio.com<\/a>\u00a0and connect with DiamiR on LinkedIn.<\/p>\n<p align=\"justify\">\n        <b>Merger between Aptorum Group and DiamiR Biosciences<\/b>\n      <\/p>\n<p align=\"justify\">As was previously announced on July 16, 2025, Aptorum Group and DiamiR entered into a definitive agreement for an all-stock merger transaction. As a result of this transaction, which remains subject to stockholder approval of both companies and other customary closing conditions, DiamiR will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger. The transaction is expected to close in the first half of fiscal 2026.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ctarget,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cpropose,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cforecast,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook,\u201d and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding the consummation and closing of the proposed merger, the satisfactory completion of all conditions to the merger, the shareholder\u2019s approval necessary for the issuance of shares in the merger and re-domestication of Aptorum, Aptorum\u2019s and DiamiR\u2019s\u00a0 ability to successfully operate its business and provide value to stockholders after completion of the merger, Aptorum\u2019s and DiamiR\u2019s future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Aptorum\u2019s and DiamiR\u2019s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Aptorum and DiamiR operate may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Aptorum and DiamiR operate, the financial markets, economic, business and regulatory and other factors, such as Aptorum\u2019s and DiamiR\u2019s ability to execute on their strategies. More detailed information about risk factors can be found in the Aptorum\u2019s Annual Report on Form 20-F under the heading \u201cRisk Factors,\u201d and in other reports filed by the Aptorum, including reports on Form 6-K and the registration statement on Form S-4 filed with the SEC on October 6, 2025. Aptorum and DiamiR do not undertake any duty to update forward-looking statements after the date of this press release.<\/p>\n<p align=\"justify\">\n        <b>No Offer or Solicitation<\/b>\n      <\/p>\n<p align=\"justify\">This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended.<\/p>\n<p align=\"justify\">\n        <b>Additional Information About the Proposed Merger and Where to Find It<\/b>\n      <\/p>\n<p align=\"justify\">In connection with the merger, Aptorum filed a current report on Form 6-K to disclose additional details about the merger and a registration statement on Form S-4 with the SEC, and will mail notices of shareholders\u2019 meetings and other relevant documents to its shareholders. Investors and security holders of Aptorum are advised to read the Form S-4, and amendments thereto, the notice to shareholders, and amendments thereto, in connection with Aptorum\u2019s solicitation of proxies for its shareholder&#8217; meeting to be held to approve the proposed merger because the notice to shareholders will contain important information about the transaction and the parties to the transaction, and stockholders are urged to read the proxy statement\/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the merger and related proposals. The notices to shareholders will be mailed to Aptorum\u2019s shareholders as of a record date to be established for voting on the transactions. Shareholders will also be able to obtain copies of the notice, without charge, once available, at the SEC&#8217;s website at\u00a0<b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UTi_NzMdw5_9W6_4iOQTvakDjfozkFKquYBMohmC-qQTb58kki7bItPEdniODAflFbonvRHpwZdi1MVjcCiOAw==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a><\/b>\u00a0or by directing a request to: Ian Huen, telephone: +44 20 80929299.<\/p>\n<p align=\"justify\">This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\u00a0 A copy of Aptorum&#8217;s registration statement on Form S-4 can be viewed on the SEC&#8217;s website.<\/p>\n<p align=\"justify\">\n        <b>Participants in the Solicitation<\/b>\n      <\/p>\n<p align=\"justify\">Aptorum Group, DiamiR and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the merger. Information about Aptorum&#8217;s directors and executive officers including a description of their interests in Aptorum is included in Aptorum\u2019s most recent Annual Report on Form 20-F, including any information incorporated therein by reference, as filed with the SEC. Additional information regarding these persons and their interests in the transaction are included in the proxy statement\/prospectus relating to the merger that was filed with the SEC in a registration statement on Form S-4 on January 21, 2026. These documents can be obtained free of charge from the sources indicated above.<\/p>\n<p>For more information, please contact:\u00a0<\/p>\n<p>\n        <b>Aptorum Group Limited<\/b>\n      <\/p>\n<p>Investor Relations Department<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Vm2sFhG2xM1hStP3kI4ya0w-5p4HG4tnrfNgm1kTL6Mxo_oUQSe2eTH0u6xfOOQzvxg5hFqTWpmu_vPKi38uBflJTaNcplQUxdSM_5lBdWuez2gJCikVkOkDaln3Z6AuId6-qREPWQhcW3wN3nsZNg==\" rel=\"nofollow\" target=\"_blank\">investor.relations@aptorumgroup.com<\/a>\n      <\/p>\n<p>+44 20 80929299<\/p>\n<p>\n        <b>DiamiR Biosciences<\/b>\n      <\/p>\n<p>Alidad Mireskandari, PhD<br \/>203-570-8275<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QWsblZiEZUCXo6-f5cVDwyZM7FtY4Dc3gCh5rWebjufKfO8t2WrZYxu6XLfiCPIkzps2oGijDL7xGhiokBAiasUBEZdKLS3l8dOmEyTxOzTlu2Bpc7oga6GXWljncNY1\" rel=\"nofollow\" target=\"_blank\">amireskandari@diamirbio.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjJiNTg2OTQtODg4ZS00ZjQ5LTg4YjAtZTk2MGUxOTdkMGNhLTUwMDEzMTQwMi0yMDI2LTAzLTEwLWVu\/tiny\/Aptorum-Group-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) &#8212; Aptorum Group Limited (NASDAQ: APM) (&#8220;Aptorum Group\u201d or \u201cAptorum\u201d), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (\u201cDiamiR\u201d), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled &#8220;Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens\u201d in Diagnostics, (https:\/\/doi.org\/10.3390\/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, conducted in collaboration with clinical researchers at the Perelman School of Medicine at the University of Pennsylvania, demonstrates the feasibility of detecting glioblastoma (GBM) \u2014 the most aggressive and lethal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943177","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) &#8212; Aptorum Group Limited (NASDAQ: APM) (&#8220;Aptorum Group\u201d or \u201cAptorum\u201d), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (\u201cDiamiR\u201d), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled &#8220;Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens\u201d in Diagnostics, (https:\/\/doi.org\/10.3390\/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, conducted in collaboration with clinical researchers at the Perelman School of Medicine at the University of Pennsylvania, demonstrates the feasibility of detecting glioblastoma (GBM) \u2014 the most aggressive and lethal &hellip; Continue reading &quot;Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T13:32:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania\",\"datePublished\":\"2026-03-10T13:32:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/\"},\"wordCount\":1691,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/\",\"name\":\"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==\",\"datePublished\":\"2026-03-10T13:32:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/","og_locale":"en_US","og_type":"article","og_title":"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Market Newsdesk","og_description":"NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) &#8212; Aptorum Group Limited (NASDAQ: APM) (&#8220;Aptorum Group\u201d or \u201cAptorum\u201d), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (\u201cDiamiR\u201d), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled &#8220;Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens\u201d in Diagnostics, (https:\/\/doi.org\/10.3390\/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, conducted in collaboration with clinical researchers at the Perelman School of Medicine at the University of Pennsylvania, demonstrates the feasibility of detecting glioblastoma (GBM) \u2014 the most aggressive and lethal &hellip; Continue reading \"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-10T13:32:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania","datePublished":"2026-03-10T13:32:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/"},"wordCount":1691,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/","name":"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==","datePublished":"2026-03-10T13:32:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2OTEyOSM3NDc3MzczIzUwMDEzMTQwMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aptorum-group-and-diamir-biosciences-announce-publication-of-microrna-glioblastoma-biomarker-study-in-diagnostics-in-collaboration-with-the-university-of-pennsylvania\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943177"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943177\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}